Ondansetron Enexi (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the central nervous system and gastrointestinal tract. This inhibition stops the signaling cascade that triggers the vomiting reflex, thereby reducing nausea and vomiting.

The dosing regimen for Ondansetron Enexi is determined by the prescribing clinician based on the indication, patient age, weight, and renal or hepatic function. The prescriber sets the appropriate dose and administration schedule.

Safety data are limited; ondansetron should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering rapid onset and high efficacy for chemotherapy‑induced nausea. Compared with dopamine antagonists, it has a lower risk of extrapyramidal side effects, though QT prolongation requires monitoring.

Store the product at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability.

Ondansetron Enexi is given as an intravenous injection. The healthcare professional administers the solution over a short period, typically as a bolus or slow infusion, according to the prescriber's instructions.

Serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Prompt medical attention is required if these occur.

Patients with known hypersensitivity to ondansetron or any component of the formulation should avoid use. Those with congenital long QT syndrome or who are taking other QT‑prolonging drugs should be evaluated carefully before administration.